by Plus Therapeutics | Apr 22, 2025 | GBM
REYOBIQ™ Clinical Trial for Recurrent Glioma Featured in Oncolytics Today We’re proud to share that Plus Therapeutics’ innovative work on REYOBIQ™ (rhenium-186 Re obisbemeda) has been featured as the cover story in the latest issue of Oncolytics Today, published by...
by Plus Therapeutics | Apr 12, 2025 | GBM, LM, PBC, Uncategorized
Advancing Radiotherapeutic Solutions for Rare Cancers At Plus Therapeutics, our mission is clear: to develop safe, effective, and lasting solutions for patients facing rare and hard-to-treat cancers. Every day, our dedicated team works alongside clinicians and...
by Plus Therapeutics | Apr 8, 2025 | GBM, LM, PBC, Uncategorized
The Power of Radionuclide-Based Therapies in Modern Cancer Treatment Radionuclide-based therapies represent a rapidly evolving frontier in precision oncology, offering targeted treatment options for a wide range of cancer types. These therapies utilize radionuclides...
by Plus Therapeutics | Apr 2, 2025 | GBM, LM, PBC, Uncategorized
A Novel Radiotherapeutic Platform Targeting Complex Tumors with Precision At Plus Therapeutics, we’re pioneering a next-generation radiotherapeutic platform designed to deliver targeted cancer treatment with high precision and minimal toxicity. Our platform is powered...
by Plus Therapeutics | Mar 26, 2025 | GBM, LM, PBC, Uncategorized
REYOBIQ™: A Promising Radiotherapeutic Advancing Treatment for Glioblastoma, Leptomeningeal Metastases, and Pediatric Brain Cancers At Plus Therapeutics, we’re advancing the future of cancer care with REYOBIQ™ (rhenium-186 Re obisbemeda), our lead targeted...
by Plus Therapeutics | Mar 20, 2025 | GBM, LM, PBC, Uncategorized
Introducing REYOBIQ™: The FDA-Accepted Proprietary Name for Plus Therapeutics’ Lead Drug Candidate Big News from Plus Therapeutics! The U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary name REYOBIQ™ (rhenium Re186 obisbemeda) for our...
Recent Comments